B M Meyers1, R Cosby2, F Quereshy3, D Jonker4. 1. Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, ON. 2. Program in Evidence-Based Care, Department of Oncology, McMaster University, Juravinski Campus, Hamilton, ON. 3. Toronto Western Hospital, Toronto, ON. 4. The Ottawa Hospital Cancer Centre, Ottawa, ON.
Abstract
BACKGROUND: Updated practice guidelines on adjuvant chemotherapy for completely resected colon cancer are lacking. In 2008, Cancer Care Ontario's Program in Evidence-Based Care developed a guideline on adjuvant therapy for stages ii and iii colon cancer. With newer regimens being assessed in this patient population and older agents being either abandoned because of non-effectiveness or replaced by agents that are more efficacious, a full update of the original guideline was undertaken. METHODS: Literature searches (January 1987 to August 2015) of medline, embase, and the Cochrane Library were conducted; in addition, abstracts from the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress were reviewed (the latter for January 2007 to August 2015). A practice guideline was drafted that was then scrutinized by internal and external reviewers whose comments were incorporated into the final guideline. RESULTS: Twenty-six unique reports of eighteen randomized controlled trials and thirteen unique reports of twelve meta-analyses or pooled analyses were included in the evidence base. The 5 recommendations developed included 3 for stage ii colon cancer and 2 for stage iii colon cancer. CONCLUSIONS: Patients with completely resected stage iii colon cancer should be offered adjuvant 5-fluorouracil (5fu)-based chemotherapy with or without oxaliplatin (based on definitive data for improvements in survival and disease-free survival). Patients with resected stage ii colon cancer without "high-risk" features should not receive adjuvant chemotherapy. For patients with "high-risk" features, 5fu-based chemotherapy with or without oxaliplatin should be offered, although no clinical trials have been conducted to conclusively demonstrate the same benefits seen in stage iii colon cancer.
BACKGROUND: Updated practice guidelines on adjuvant chemotherapy for completely resected colon cancer are lacking. In 2008, Cancer Care Ontario's Program in Evidence-Based Care developed a guideline on adjuvant therapy for stages ii and iii colon cancer. With newer regimens being assessed in this patient population and older agents being either abandoned because of non-effectiveness or replaced by agents that are more efficacious, a full update of the original guideline was undertaken. METHODS: Literature searches (January 1987 to August 2015) of medline, embase, and the Cochrane Library were conducted; in addition, abstracts from the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress were reviewed (the latter for January 2007 to August 2015). A practice guideline was drafted that was then scrutinized by internal and external reviewers whose comments were incorporated into the final guideline. RESULTS: Twenty-six unique reports of eighteen randomized controlled trials and thirteen unique reports of twelve meta-analyses or pooled analyses were included in the evidence base. The 5 recommendations developed included 3 for stage ii colon cancer and 2 for stage iii colon cancer. CONCLUSIONS:Patients with completely resected stage iii colon cancer should be offered adjuvant 5-fluorouracil (5fu)-based chemotherapy with or without oxaliplatin (based on definitive data for improvements in survival and disease-free survival). Patients with resected stage ii colon cancer without "high-risk" features should not receive adjuvant chemotherapy. For patients with "high-risk" features, 5fu-based chemotherapy with or without oxaliplatin should be offered, although no clinical trials have been conducted to conclusively demonstrate the same benefits seen in stage iii colon cancer.
Entities:
Keywords:
Adjuvant treatment; chemotherapy; colon cancer; practice guidelines
Authors: Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Bengt Glimelius; Olav Dahl; Björn Cedermark; Anders Jakobsen; Søren M Bentzen; Hans Starkhammar; Henrik Grönberg; Ragnar Hultborn; Maria Albertsson; Lars Påhlman; Kjell-Magne Tveit Journal: Acta Oncol Date: 2005 Impact factor: 4.089
Authors: Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: Jacek A Kopec; Greg Yothers; Patricia A Ganz; Stephanie R Land; Reena S Cecchini; H Samuel Wieand; Barry C Lembersky; Norman Wolmark Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: C Twelves; W Scheithauer; J McKendrick; J-F Seitz; G Van Hazel; A Wong; E Díaz-Rubio; F Gilberg; J Cassidy Journal: Ann Oncol Date: 2011-09-06 Impact factor: 32.976
Authors: A Zaniboni; R Labianca; S Marsoni; V Torri; P Mosconi; R Grilli; G Apolone; S Cifani; A Tinazzi Journal: Cancer Date: 1998-06-01 Impact factor: 6.860
Authors: G Francini; R Petrioli; L Lorenzini; S Mancini; S Armenio; G Tanzini; S Marsili; A Aquino; G Marzocca; S Civitelli Journal: Gastroenterology Date: 1994-04 Impact factor: 22.682
Authors: W Schippinger; H Samonigg; R Schaberl-Moser; R Greil; R Thödtmann; J Tschmelitsch; M Jagoditsch; G G Steger; R Jakesz; F Herbst; F Hofbauer; H Rabl; P Wohlmuth; M Gnant; J Thaler Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640
Authors: Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie Journal: J Urol Date: 2017-05-04 Impact factor: 7.450
Authors: Wong Hoi She; Tan To Cheung; Ka Wing Ma; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; Chung Mau Lo Journal: Langenbecks Arch Surg Date: 2021-05-22 Impact factor: 3.445
Authors: Devon J Boyne; Colleen A Cuthbert; Dylan E O'Sullivan; Tolulope T Sajobi; Robert J Hilsden; Christine M Friedenreich; Winson Y Cheung; Darren R Brenner Journal: JAMA Netw Open Date: 2019-05-03
Authors: Du Fenqi; Liu Yupeng; Zhang Qiuju; Yuan Chao; Song Wenjie; Xia Tianyi; Guo Junnan; Xue Weinan; Jiang Xiufeng; Bai Junge; Jia Chenyang; Xi Hua; Li Yien; Bai Xuefeng; Liu Yanlong Journal: Front Oncol Date: 2022-01-11 Impact factor: 6.244